10-K: Sunshine Biopharma Reports Increased Revenue but Net Loss for Fiscal Year 2024

Sunshine Biopharma's 10-K filing reveals a revenue increase driven by expanded generic drug sales in Canada, but the company still reports a net loss for the year ended December 31, 2024.

Summary

• Sunshine Biopharma Inc. reported revenues of $34.87 million for the year ended December 31, 2024, compared to $24.09 million in 2023, driven by expanded sales efforts in Canada and an increased number of products offered.
• The cost of sales increased to $24.20 million in 2024 from $15.75 million in 2023, primarily due to higher professional allowances incurred on sales outside of Quebec.
• General and administrative expenses rose to $16.48 million in 2024 from $13.12 million in 2023, reflecting the expansion of sales operations.
• The company incurred a net loss of $5.13 million for the year ended December 31, 2024, compared to a net loss of $4.51 million for the year ended December 31, 2023.
• As of December 31, 2024, Sunshine Biopharma had cash and cash equivalents of $9.69 million.
• The company believes its existing cash will be sufficient to fund its pharmaceutical sales operations and research and development activities for the next 24 months, but anticipates needing to raise additional capital in the future.
• Sunshine Biopharma has 70 generic prescription drugs on the market in Canada and 64 additional drugs in its pipeline, with 13 anticipated to launch during the remainder of 2025.
• The company is developing K1.1 mRNA for liver cancer and SBFM-PL4 as a protease inhibitor for SARS Coronavirus infections, both currently in animal testing stages.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. Revenue growth is positive, but the increasing net loss and the need for future capital raises temper the outlook. The company is making progress in its drug development programs, but these are still in early stages and face significant regulatory and competitive hurdles.

Positives

• Revenue increased by approximately $10.8 million in 2024 compared to 2023.
• The company anticipates launching 13 additional drugs during the remainder of 2025.
• Sunshine Biopharma has $9.69 million in cash and cash equivalents as of December 31, 2024.
• The company is actively developing K1.1 mRNA for liver cancer and SBFM-PL4 for SARS Coronavirus infections.
• The Canadian generic pharmaceuticals market is expected to grow significantly, reaching $19.2 billion USD by 2032.

Negatives

• The company incurred a net loss of $5.13 million for the year ended December 31, 2024.
• General and administrative expenses increased by $3.36 million in 2024.
• The company anticipates needing to raise additional capital in the future.
• The company faces intense competition in both the generic pharmaceutical and proprietary drug development markets.
• The company's future success depends on obtaining regulatory approval for its non-generic pharmaceutical product candidates.

Risks

• The company may never achieve profitability.
• The generic pharmaceutical business is subject to significant risks, including macroeconomic instability and supply chain discontinuities.
• Sales of generic products may be adversely affected by the drug regulatory environment in Canada.
• The company may experience delays in launching new generic products.
• The company may not receive required regulatory approval for its non-generic pharmaceutical product candidates.
• The company will require additional funding to satisfy its future capital needs, which may not be available.
• The company may be sued or become a party to litigation.
• The company may be unable to attract and retain qualified scientific, technical, and key management personnel.
• The company's business exposes it to potential product liability risks.
• The company faces regulation and risks related to hazardous materials and environmental laws.
• Third party manufacturers may not be able to manufacture the company's pharmaceutical product candidates.
• The company may be unable to establish sales and marketing capabilities for its pharmaceutical product candidates.
• The company's business will not be profitable if its proprietary drug product candidates do not achieve and maintain market acceptance.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company's proprietary drug product candidates and its development and collaboration efforts depend on its intellectual property rights.
• The company may not be able to maintain the confidentiality of its technology and other confidential information.
• The implementation of the company's business plan may result in a period of rapid growth that will impose a significant burden on its current administrative and operational resources.
• A significant or prolonged economic downturn could have a material adverse effect on the company's results of operations.
• The failure of the company's service providers and suppliers to supply quality services and materials in sufficient quantities, at a favorable price, and in a timely fashion could adversely affect the results of its operations.
• The company's business is subject to the effects of adverse publicity.
• The company's manufacturing and third-party fulfillment activities are subject to certain risks.
• There is significant volatility in the price and trading volume of the company's common stock.
• If the company is unable to continue to meet the listing requirements of Nasdaq, its common stock will be delisted.
• The company does not intend to pay dividends on its common stock for the foreseeable future.
• The company's articles of incorporation allow for its board to create new series of preferred stock without further approval by its stockholders, which could adversely affect the rights of the holders of its common stock.
• Additional stock offerings in the future or the issuance of stock upon exercise of outstanding warrants may dilute then-existing shareholders percentage ownership in the company.

Future Outlook

The company believes its existing cash will be sufficient to fund its pharmaceutical sales operations and research and development activities for the next 24 months, but anticipates needing to raise additional capital in the future, including for further research and development activities and possibly clinical trials, as well as expansion of its generic pharmaceutical operations.

Industry Context

The Canadian generic pharmaceuticals market was valued at approximately $9.7 billion USD in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 7.9%, reaching $19.2 billion USD by the end of 2032. The company faces competition from numerous other entities engaged in oncology therapeutics development that have greater resources than the resources presently available to it.

Comparison to Industry Standards

• The document mentions that the top 3 generic players in Canada hold approximately 50% share of the total market, indicating a concentrated market structure.
• Nora Pharma is described as relatively new in this space but has demonstrated one of the fastest year-over-year sales growth amongst its peers, suggesting a strong growth trajectory compared to industry averages.
• The company's Anti-Coronavirus drug development project is in direct competition with several companies in the U.S. that have developed effective vaccines or treatment options for COVID-19, including Pfizer, Merck, Gilead, Eli Lilly, and Regeneron, indicating a highly competitive landscape.
• In the area of anticancer drug development, the company competes with large publicly and privately held companies engaged in developing new cancer therapies, including Merck, Amgen, Roche, Pfizer, Bristol-Myers Squibb and Novartis, highlighting the presence of major industry players in the same therapeutic area.

Management Changes

Related Party Transactions

• The company paid its officers cash compensation totaling $1,850,243 and $1,515,000 for the years ended December 31, 2024 and 2023, respectively.
• Of these amounts attributable to the company's CEO, $800,000 and $0, respectively was paid to Advanomics Corporation, a company controlled by the CEO of the company.
• In addition, the company's CEO was paid $12,000 in 2024 through the issuance of 120,000 shares of Series B Preferred Stock valued at $12,000.
• The company paid its five directors cash compensation of $80,000 each, totaling $400,000 for the years ended December 31, 2024 and 2023.

Stakeholder Impact

• Shareholders may experience dilution if the company issues additional shares of common stock or securities convertible or exercisable for shares of common stock.
• Employees' job security is dependent on the company's ability to achieve profitability and secure additional funding.
• Customers in Canada benefit from the availability of affordable generic drugs.
• Suppliers and creditors are impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• Continue expanding sales operations in Canada.
• Launch 13 additional generic drugs during the remainder of 2025.
• Advance the development of K1.1 mRNA and SBFM-PL4 through animal testing.
• Seek regulatory approval for proprietary drug candidates.
• Raise additional capital to fund operations and research and development activities.

Key Dates

Keywords

Sunshine Biopharma, generic drugs, pharmaceuticals, K1.1 mRNA, SBFM-PL4, Nora Pharma, revenue, net loss, clinical trials, regulatory approval, biopharma, oncology, antivirals